Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 8OTHER 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 1CNS 1Breast 1

Conditions

Melanoma 1Central Nervous System Diseases 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Cisplatin 1041Cyclophosphamide 973Carboplatin 954Radiotherapy 893Bevacizumab 847Gemcitabine 817pembrolizumab 759Paclitaxel 738Docetaxel 734Oxaliplatin 706Capecitabine 649Fluorouracil 564Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 402Leucovorin 377Cytarabine 342Cetuximab 340Lenalidomide 326Trastuzumab 323Pemetrexed 315durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 278Temozolomide 275Prednisone 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × OTHER × sagopilone × Clear all
NCT00598507 2013-12-11

Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
35 enrolled 8 charts
Dermatologic

Melanoma

NCT00496379 2013-03-14

ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases

Dana-Farber Cancer Institute

Phase 2 Terminated
15 enrolled 10 charts
BreastCNS

Brain Neoplasms, Breast Neoplasms, Central Nervous System Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡